Nuclear Medicine
MIBG 131 WITHOUT CARRIER (R&D)
Name:
MIBG 131 without carrier (R&D)
Active Principle:
Iobenguan 131I
Therapeutic Action:
It is a radioactive therapeutic agent indicated for the treatment of adult and pediatric patients 12 years of age and older with iobenguane-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic antineoplastic therapy.
Nuclear Medicine
MIBG 131 WITHOUT CARRIER (R&D)
Name:
MIBG 131 without carrier (R&D)
Active Principle:
Iobenguan 131I
Therapeutic Action:
It is a radioactive therapeutic agent indicated for the treatment of adult and pediatric patients 12 years of age and older with iobenguane-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic antineoplastic therapy.
RELATED PRODUCTS
-
STANNOUS CHLORIDE
STANNOUS CHLORIDEIt is indicated for: - Performing scintigraphic studies of the blood pool of the heart and great vessels. - Circulatory and placental studies. - Evaluation of gastrointestinal bleeding (especially to locate... -
IODOSOL 123I (R&D)
IODOSOL 123I (R&D)Sodium iodide (123I) solution is indicated as a diagnostic agent to evaluate thyroid function and/or morphology by scintigraphy and radioactive iodine uptake test. -
PYROPHOSPHATE
PYROPHOSPHATEIt is indicated for performing bone scintigraphy, detection of cardiac pathologies and "in vivo" and "in vitro" marking of erythrocytes. 1) In vivo, in vitro or in vivo/in vitro marking of red blood cells to...

